Medicus Pharma (NASDAQ:MDCX - Get Free Report)'s stock had its "buy" rating restated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $14.00 price objective on the stock. D. Boral Capital's price objective would indicate a potential upside of 217.46% from the company's previous close.
Separately, D Boral Capital raised Medicus Pharma to a "strong-buy" rating in a research report on Monday, April 14th.
Check Out Our Latest Analysis on MDCX
Medicus Pharma Stock Performance
MDCX traded up $0.09 during trading hours on Monday, hitting $4.41. The company's stock had a trading volume of 45,584 shares, compared to its average volume of 51,711. The firm has a 50-day moving average of $3.61. Medicus Pharma has a 12 month low of $1.80 and a 12 month high of $6.00.
Medicus Pharma (NASDAQ:MDCX - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. As a group, research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC purchased a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma comprises approximately 1.3% of Interchange Capital Partners LLC's portfolio, making the stock its 15th largest holding. Interchange Capital Partners LLC owned about 13.43% of Medicus Pharma at the end of the most recent quarter.
About Medicus Pharma
(
Get Free Report)
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
Before you consider Medicus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicus Pharma wasn't on the list.
While Medicus Pharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
